Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidural etanercept for sciatica
ACTRN12609000207213Phase 2Completed
- Sponsor
- BioAssets Development Corporation
- Start
- Mar 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of etanercept in lumbosacral radiculopathy and Sciatica (4 arms), sponsored by BioAssets Development Corporation. Primary endpoint: Safety of epidural etanercept versus placebo. Started Mar 2009; status: completed.
02
Drugs
etanercept
03
Conditions
lumbosacral radiculopathySciatica
Beyond the preview
Go deeper on ACTRN12609000207213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000207213.